Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded

Allogeneic adipose tissue-derived mesenchymal stem cells (AD-MSCs) are being investigated as a promising treatment option for various medical conditions in several clinical trials. These stem cells, extracted from adipose (fat) tissue of healthy donors, have shown potential in treating complex perianal fistulas in Crohn’s disease, knee osteoarthritis, epidermolysis bullosa, and ulcerative colitis. The trials aim to evaluate the safety, efficacy, and optimal dosing of AD-MSCs when administered through different routes such as intralesional, intra-articular, or intradermal injections.

What are Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells?
Conditions Being Treated with AD-MSCs
How are AD-MSCs Administered?
Safety and Efficacy
Ongoing Research and Clinical Trials
Patient Considerations

What are Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells?

Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (AD-MSCs) are a type of cell therapy that shows promise in treating various medical conditions. These cells are extracted from fat tissue (adipose tissue) of healthy donors and then expanded in a laboratory setting. The term “allogeneic” means that the cells come from a donor, not the patient themselves^[1].

AD-MSCs are a type of adult stem cell that have the ability to develop into different types of cells in the body. They are known for their potential to:

Reduce inflammation
Promote tissue repair and regeneration
Modulate the immune system

Conditions Being Treated with AD-MSCs

Research is ongoing to explore the potential of AD-MSCs in treating various conditions. Some of the conditions being studied include:

Complex perianal fistulas in Crohn’s disease: AD-MSCs are being investigated for their ability to heal fistulas (abnormal connections between organs) in patients with Crohn’s disease^[2].
Knee osteoarthritis: Studies are examining whether AD-MSCs can help regenerate cartilage and reduce pain in patients with knee osteoarthritis^[1].
Ulcerative colitis: Researchers are exploring the potential of AD-MSCs to reduce inflammation in the colon of patients with ulcerative colitis^[3].
Epidermolysis bullosa: This rare genetic skin condition is being studied to see if AD-MSCs can help improve wound healing^[4].

How are AD-MSCs Administered?

The method of administering AD-MSCs depends on the condition being treated. Some common methods include:

Intralesional injection: Directly injecting the cells into the affected area, such as into fistulas in Crohn’s disease^[2].
Intra-articular injection: Injecting the cells directly into a joint, as in the case of knee osteoarthritis^[1].
Intradermal injection: Injecting the cells into the skin, which may be used in conditions like epidermolysis bullosa^[4].

Safety and Efficacy

While AD-MSCs show promise, it’s important to note that many studies are still in early phases, focusing on safety and initial efficacy. Here are some key points:

Safety is a primary concern in all studies, with researchers closely monitoring for any adverse events^[2]^[1]^[3]^[4].
Early results in some studies have shown potential benefits, such as improved healing of fistulas in Crohn’s disease^[2].
Researchers are still determining the optimal dosage and frequency of treatments for different conditions^[3].

Ongoing Research and Clinical Trials

Several clinical trials are currently underway to further investigate the potential of AD-MSCs:

A study is examining the long-term safety and efficacy of repeated treatments with AD-MSCs (known as darvadstrocel) in adult patients with complex perianal fistulas in Crohn’s disease^[2].
Another trial is investigating the use of AD-MSCs in pediatric patients with complex perianal fistulas in Crohn’s disease^[5].
Researchers are studying the effects of AD-MSCs on knee osteoarthritis, looking at factors such as pain reduction and cartilage regeneration^[1].
A trial is exploring the use of AD-MSCs as a local treatment for ulcerative colitis, examining their ability to reduce inflammation in the colon^[3].
The safety and efficacy of AD-MSCs are being studied in patients with epidermolysis bullosa, a rare genetic skin condition^[4].

Patient Considerations

If you’re considering participating in a clinical trial or treatment involving AD-MSCs, here are some important points to consider:

Eligibility: Each study has specific inclusion and exclusion criteria. These may include factors such as age, disease severity, and previous treatments^[2]^[1]^[3]^[4].
Potential risks: While AD-MSCs have shown promise, there may be risks involved. These could include reactions at the injection site, allergic reactions, or other unforeseen side effects^[2]^[1]^[3]^[4].
Follow-up care: Participating in a clinical trial often involves regular follow-up visits and tests to monitor your progress and any potential side effects^[2]^[1]^[3]^[4].
Informed consent: Before participating in any study, you’ll be asked to provide informed consent. This means you’ll be given detailed information about the study and have the opportunity to ask questions^[2]^[1]^[3]^[4].

While AD-MSCs show promise in treating various conditions, it’s important to remember that research is still ongoing. Always consult with your healthcare provider to determine if participating in a clinical trial or receiving this treatment is appropriate for your specific situation.

Condition	Trial Phase	Administration Route	Key Objectives	Primary Endpoints
Complex Perianal Fistulas in Crohn’s Disease	Phase IV, Phase III	Intralesional injection	Evaluate long-term safety and efficacy of repeat administration	Combined remission at Week 24, Incidence of adverse events
Knee Osteoarthritis	Phase I/II	Intra-articular injection	Assess safety and clinical efficiency	Knee symptoms evaluated by KOOS score, Adverse events
Epidermolysis Bullosa	Phase I/II	Intradermal injection	Assess safety and obtain pilot efficacy data	Incidence of adverse events of special interest
Ulcerative Colitis	Phase II	Intralesional injection into mucosa	Investigate reduction in mucosal inflammation and intestinal symptoms	Reduced inflammatory activity assessed with endoscopic Mayoscore

Condition

Trial Phase

Administration Route

Key Objectives

Primary Endpoints

Complex Perianal Fistulas in Crohn’s Disease

Phase IV, Phase III

Intralesional injection

Evaluate long-term safety and efficacy of repeat administration

Combined remission at Week 24, Incidence of adverse events

Knee Osteoarthritis

Phase I/II

Intra-articular injection

Assess safety and clinical efficiency

Knee symptoms evaluated by KOOS score, Adverse events

Epidermolysis Bullosa

Phase I/II

Intradermal injection

Assess safety and obtain pilot efficacy data

Incidence of adverse events of special interest

Ulcerative Colitis

Phase II

Intralesional injection into mucosa

Investigate reduction in mucosal inflammation and intestinal symptoms

Reduced inflammatory activity assessed with endoscopic Mayoscore

Ongoing Clinical Trials on Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded

Glossary

Allogeneic: Refers to cells or tissues that are taken from a different individual of the same species. In this context, it means the stem cells are derived from a donor, not the patient themselves.
Mesenchymal Stem Cells (MSCs): A type of multipotent stem cell that can differentiate into various cell types, including bone, cartilage, muscle, and fat cells.
Adipose Tissue: Commonly known as fat tissue, it's a type of connective tissue that stores energy in the form of fat.
Perianal Fistula: An abnormal connection between the anal canal and the skin around the anus, often occurring in people with Crohn's disease.
Crohn's Disease: A type of inflammatory bowel disease that causes inflammation of the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition.
Osteoarthritis: A degenerative joint disease characterized by the breakdown of joint cartilage and underlying bone, often affecting the knees, hips, and hands.
Epidermolysis Bullosa: A group of rare genetic conditions that cause the skin to be very fragile and to blister easily in response to minor injuries or friction.
Ulcerative Colitis: A chronic inflammatory bowel disease that causes inflammation and ulcers in the digestive tract, primarily affecting the colon and rectum.
Intralesional: Refers to the administration of a substance directly into a lesion or affected area of tissue.
Intra-articular: Refers to an injection or procedure performed directly into a joint space.
Intradermal: Refers to administration within or between the layers of the skin.
Clinical Trial: A research study that prospectively assigns human participants to one or more health-related interventions to evaluate their effects on health outcomes.
Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
Efficacy: The ability of a treatment to produce a desired or intended result under ideal circumstances.

References

http://clinicaltrials.eu/trial/study-on-the-effects-of-allogeneic-adipose-derived-mesenchymal-stem-cells-and-sodium-chloride-for-patients-with-knee-osteoarthritis/
http://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-darvadstrocel-for-adults-with-crohns-disease-and-complex-perianal-fistulas/
http://clinicaltrials.eu/trial/study-on-the-use-of-allogeneic-adipose-derived-mesenchymal-stem-cells-for-treating-ulcerative-colitis-in-patients/
http://clinicaltrials.eu/trial/study-on-the-safety-of-allogeneic-adipose-tissue-derived-mesenchymal-stromal-cells-for-patients-with-epidermolysis-bullosa/
http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-allogeneic-adipose-tissue-derived-mesenchymal-stem-cells-for-treating-complex-perianal-fistulas-in-children-with-crohns-disease/

#1 Clinical Trials Search in Europe